Jorge Marrero

Hepatology · 2002–2019

A researcher in the Science corpus: 8 papers; trusts 1 researcher and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

Whom Jorge Marrero trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Jordi Bruix1 , 2
  2. J. Heimbach
  3. R. Salem
  4. María E. Reig1 , 2

Who trusts Jorge Marrero overall

  1. Z. Younossi
  2. H. B. EL‐SERAG

Papers from Jorge Marrero's perspective

Ordered by how strongly the researchers Jorge Marrero trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
  2. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. (Gastroenterology)
  3. Sorafenib in advanced hepatocellular carcinoma. (New England Journal of Medicine)
  4. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma (Gastroenterology)
  5. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
  6. A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria (Annals of Surgery)
  7. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival (Hepatology)
  8. Non-Alcoholic Fatty Liver Disease and Hepatocellular Cancer: A Systematic Review (Clinical Gastroenterology and Hepatology)
  9. Novel advancements in the management of hepatocellular carcinoma in 2008. (Journal of Hepatology)
  10. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. (American Journal of Epidemiology)

Their papers